Abaloparatide: Recombinant human PTHrP (1-34) anabolic therapy for osteoporosis.
The treatment of osteoporosis is generally either by inhibition of bone resorption with antiresorptive agents or by stimulation of bone formation with anabolic agents. Currently, teriparatide (recombinant human parathyroid hormone 1-34 [rhPTH (1-34)]) is the only available approved anabolic agent in the U.S. Other anabolic agents are under investigation however. Abaloparatide is recombinant human parathyroid hormone-related peptide 1-34. This agent is an anabolic agent that appears more potent than teriparatide, and it may have more rapid onset of fracture reduction than teriparatide. It is currently undergoing FDA review, with approval expected in 2017.
Mayo Clinic E18-A, 200 1st Street SW, Rochester, MN, 55905 USA.
Chee Kian
CK
Chew
Mayo Clinic E18-A, 200 1st Street SW, Rochester, MN, 55905 USA. Electronic address: clarke.bart@mayo.edu.
Bart L
BL
Clarke
D045930:Anabolic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D010012:Osteogenesis / Q000187:drug effects*; D010024:Osteoporosis / Q000188:drug therapy*; D044162:Parathyroid Hormone-Related Protein / Q000494:pharmacology / Q000627:therapeutic use*; D010446:Peptide Fragments / Q000494:pharmacology / Q000627:therapeutic use*; D019379:Teriparatide / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome
D045930:Anabolic Agents; D050071:Bone Density Conservation Agents; D044162:Parathyroid Hormone-Related Protein; D010446:Peptide Fragments; D019379:Teriparatide; C054296:parathyroid hormone-related protein (1-34); C000596789:abaloparatide
Abaloparatide; Anabolic agents; Fractures; Osteoporosis; PTHrP 1–34